A peptide ad is more likely to describe a product HHS’s policy covers when it names one of six peptides in a listed form and route, but the policy is not FDA approval and does not clear the ad or the seller. HHS’s interim enforcement discretion policy, published in the Federal Register on October 30, 2026, covers six peptides, each in one form and a set of listed routes, and it applies to compounding by qualifying pharmacies and physician compounders. Enforcement discretion is not FDA approval, and HHS can revise or withdraw the policy. If you saw an ad, the fastest check is three questions: which peptide, in what form and route, and who prescribes and dispenses it.
| Item | Detail |
|---|---|
| Check date | November 2, 2026 |
| Policy | HHS interim enforcement discretion policy, Docket HHS-OASH-2026-0496 |
| Published | Federal Register, October 30, 2026 |
| Comments close | November 13, 2026 |
| Peptides covered | BPC-157, TB-500, epitalon, Semax, KPV and MOTS-c, one form each |
| Status | Enforcement discretion, separate from FDA approval |
| Who may compound | Qualifying 503A pharmacies and physician compounders |
| Prescription | Patient-specific prescription required |
| LegitScript review | Certification review updated, effective November 2, 2026 |
| Price | Set by the seller; the policy sets no price |
What is a peptide ad, and what does it sell?
A peptide ad promotes a peptide product. The University of Maryland’s pharmacy overview explains that compounded drugs are prepared for patients with specific medical needs, and the PMC dermatology review of compounding describes them as mixtures prepared by a licensed pharmacist or physician. PMC dermatology compounding review adds that compounded drugs are considered off-label because the FDA has not approved them as formulated for a given use.
The six peptides in the HHS policy have their own regulatory history. The HHS policy appendix records that each peptide sat in Category 2 from September 2023 until April 22, 2026, and that FDA’s drug center recommended against listing them while the Pharmacy Compounding Advisory Committee voted in favor. LegitScript’s peptide promotion guidance states that an advisory committee recommendation authorizes no compounding, and that only a final rule changes a substance’s regulatory status.
Who may fit, and who should pause?
The people most likely to fit the policy are those whose licensed prescriber writes a patient-specific prescription for one covered peptide, in a listed form and route, filled by a qualifying 503A pharmacy. Anyone offered a peptide sold as a research chemical or a dietary supplement is in a different category. Anyone offered a combination of peptides, or a peptide that is not on the list, should pause and ask questions first.
Which peptides does the HHS policy cover?
| Peptide | Covered form | Routes listed in the policy |
|---|---|---|
| BPC-157 | Acetate | Subcutaneous, intramuscular, oral, topical |
| TB-500 | Acetate | Subcutaneous, intramuscular |
| Epitalon | Acetate | Subcutaneous, intramuscular |
| Semax | Free base | Intranasal |
| KPV | Acetate | Topical, oral |
| MOTS-c | Acetate | Subcutaneous, intramuscular |
LegitScript’s policy explainer sets out these forms and routes. The BakerHostetler policy summary adds that epitalon acetate is dispensed as injectable forms in intermittent courses. For the six peptides HHS allows, the six peptides HHS allows page covers names, safety and evidence.
The ten conditions
- A covered peptide ingredient, in the identity and route the policy specifies.
- FDA-registered sourcing and a valid certificate of analysis (COA) from a facility registered under section 510.
- Original-manufacturer verification: the original manufacturer is FDA-registered and follows current good manufacturing practice, and its physical manufacturing location appears on the COA given to the compounder.
- Reporting of compounded products, serious adverse events and product quality issues to FDA and the relevant states.
- The required label: “This is a compounded drug product. Not for resale.”
- A single active pharmaceutical ingredient. LegitScript gives combinations such as BPC-157 with TB-500, or with semaglutide, as examples that fall outside this condition.
- For oral products, documentation that the specific formulation reaches adequate oral bioavailability in humans.
- Delivery devices limited to an FDA 510(k)-cleared syringe.
- A patient-specific prescription.
- Compliance with other applicable rules, including the prohibition on compounding under insanitary conditions.
How does the offer work, claim by claim?
Take the ad apart in this order.
| Ad claim | What the policy requires | Question to ask |
|---|---|---|
| Approved or compounded? | Compounding under enforcement discretion, which is separate from FDA approval. LegitScript says implying FDA approval is a promotion signal. | Is this product compounded, and by which 503A pharmacy? |
| Which peptide? | One of the six, as a single active ingredient | Is it one of the six, with no other active ingredient? |
| Which form and route? | The form and route listed for that peptide in the table above | Does the route in the ad appear in that table? |
| Who prescribes? | A licensed physician or qualifying prescriber, with a patient-specific prescription | Is the prescription written for me, and who can I contact about it? |
| Which pharmacy? | A qualifying 503A pharmacy. 503B outsourcing facilities are a separate category. | What is the pharmacy’s name, 503A status and state license? |
| What is the monthly total? | The policy is about legal conditions and sets no price, so the price comes from the seller. | What is the full total, including shipping and any renewal charge? |
Under the policy, the prescriber writes the prescription and a qualifying pharmacy compounds the product. LegitScript says a business that partners with a separate entity to prescribe or dispense these substances still has to meet the requirements, and that the partnership is not a workaround.
What does the evidence say about these peptides?
Established facts
- HHS says compounded drugs are not reviewed by FDA for safety, effectiveness or quality before they are marketed, and that compounded drugs may pose risks to patients.
- The policy is interim. FDA continues rulemaking on the 503A bulks list, according to the BakerHostetler summary.
- The Federal Register notice on the peptide policy sets the policy’s publication date and docket.
- For what trials in people have found, read peptides human studies in our research library.
What the sellers say
Any benefit an ad describes is the seller’s own claim. Test it against the list of promotion signals later on this page.
Our reading
The policy is a conditional compounding allowance. LegitScript’s explainer treats enforcement discretion as separate from FDA approval, and it says enforcement discretion establishes neither the safety nor the effectiveness of the compounded products. Read any ad with that in mind.
Open questions
- Which human studies apply to the exact peptide, form and route you are offered? Ask the prescriber to name them.
- What side effects are documented for that product? Ask the prescriber and pharmacy for written information.
What will it cost, and what is the total commitment?
Look for shipping, any consultation or pharmacy charge, and any renewal charge.
The BakerHostetler summary says epitalon acetate is dispensed in intermittent courses. Ask how many courses a prescription covers and whether it renews automatically before you agree to anything.
What are the safety risks and side effects?
HHS says compounded drugs may pose risks to patients, and it may revisit the policy in whole or in part if a safety signal or product quality issue arises.
The University of Maryland’s pharmacy overview says compounded drugs present a greater risk to patients than FDA-approved drugs, and that poor-quality compounded drugs have led to serious harm. It cites a 2012 fungal meningitis outbreak linked to steroid injections compounded by the New England Compounding Center, which led to more than 60 deaths and 750 cases of infection. The University of Maryland compounding overview is the source for that history.
The PMC review says that, except for 503B facilities, compounding pharmacies are not required to report adverse events to the FDA, so the safety profiles of many compounded formulations remain unknown.
PhRMA’s compounding explainer comes from the drug industry trade group, which says mass-produced compounded drugs marketed directly to patients raise serious safety and public health concerns.
For side effects of the specific product, ask the prescriber for written side-effect information for that form and route. The policy limits co-packaged or containing delivery devices to an FDA 510(k)-cleared syringe, and LegitScript says clearance of a different device, such as an injector pen, does not satisfy this condition.
Is the seller legit? Checks before you pay
LegitScript describes itself as a third-party certification organization, and its review considers the specific ingredient, formulation, route of administration, compounding facility and supply chain. Certification does not guarantee advertising or payment access. Use the steps below to check the seller yourself.
- Confirm the peptide is one of the six, in its covered form and route.
- Confirm the pharmacy is a state-licensed 503A pharmacy. The policy does not cover 503B outsourcing facilities.
- Ask for the COA and check that it names the physical manufacturing location and an FDA-registered original manufacturer.
- Read the renewal and refund terms on the order page and save a copy before paying.
- Search the FDA compounding inspections and warning letters page for the pharmacy’s name. FDA suggests searching the Warning Letter Database for “telehealth” to find warning letters to telehealth companies.
What are the alternatives, including FDA-approved options and doing nothing?
| Option | What the sources say | Where to check |
|---|---|---|
| FDA-approved medicine | Reviewed by FDA for safety, effectiveness and quality before marketing, which HHS draws as the key difference from compounded drugs | Ask a clinician whether an FDA-approved product covers the same need |
| Compounded peptide under the policy | Enforcement discretion for six peptides, with a patient-specific prescription and a 503A pharmacy | The ten conditions above and the pharmacy’s license |
| Doing nothing | A choice to discuss with a clinician | Your clinician |
The PMC review says it is good medical and legal practice for prescribers to use FDA-cleared products to the fullest extent possible. It also says compounding may be a good option when a patient needs a product that is not commercially available. The same review says FDA does not treat a price difference between a commercial product and a compounded copy as a valid reason to prescribe the compounded drug. For the FDA status of one peptide, the Semax peptide guide covers product types and FDA status.
Decision table: when to take a closer look, and when to pause
| May be worth a closer look when | Pause or ask when |
|---|---|
| The ad names one of the six peptides in its listed form and route | The ad names a peptide on no list, or combines several active ingredients |
| A licensed prescriber writes a patient-specific prescription for you | The product is offered as a research chemical or dietary supplement, or without a prescription |
| The pharmacy is a state-licensed 503A pharmacy | The compounder is a 503B outsourcing facility, which falls under a separate category |
| The seller names the original manufacturer, FDA registration and a COA that shows the manufacturing location | The ad says FDA-approved, claims a peptide “repairs” or “heals” a condition, or uses unsupported proof language |
| Renewal and refund terms appear on the order page before checkout | Renewal or refund terms appear only after you have paid, or cannot be found |
How do I verify a peptide product before paying?
- Write down the peptide, form and route the ad names, and match them to the table of covered peptides.
- Ask the prescriber whether a patient-specific prescription would be written for you.
- Ask the pharmacy for its name, 503A status and state license.
- Ask for the COA and check that it names the physical manufacturing location.
- Search the FDA compounding inspections and warning letters page for the pharmacy’s name.
- Get the full total, renewal and refund terms in writing before paying.
- Ask your clinician about FDA-approved alternatives before you decide.
Can you run peptide ads on Facebook, and are peptide ads allowed?
Advertising platforms and payment providers set their own policies. LegitScript says its updates do not change those requirements, that certification does not guarantee access to them, and that platforms may take time to align with its timeline. A product can meet the HHS conditions and still face a platform’s own rules.
Ads that fit the policy are for covered peptides, in listed form and route, from qualifying compounders. LegitScript says offering or advertising a peptide that falls outside the policy, and is not otherwise eligible for compounding, remains a barrier to certification.
I saw a BPC-157 ad on Instagram. What do I check?
BPC-157 is covered as acetate, with subcutaneous, intramuscular, oral or topical routes. Oral products need documentation that the specific formulation reaches adequate oral bioavailability in humans. Check the ad’s form and route against that, and check whether the ad names a pharmacy and prescriber. Instagram’s advertising rules are set by the platform and apply on top of the HHS conditions.
What must a peptide ad not claim?
LegitScript’s peptide promotion guidance lists the signals that content has moved into promotion:
- Efficacy or safety claims about a peptide, especially compared with FDA-approved medications.
- Dosing recommendations for a drug that is not FDA-approved.
- Specific treatment benefits, such as saying a peptide “repairs” or “heals” a condition.
- Calling a peptide proven through clinical research, or scientifically backed, without a clear disclosure that most available research has not been conducted in humans.
- Implying or stating that a substance is FDA-approved or legally permitted for compounding.
- Labels or marketing that suggest enforcement discretion means FDA approval. The LegitScript explainer says businesses should avoid this.
What is peptide addiction?
If you are asking about dependence or addiction to a peptide, put the question to the prescriber or pharmacist for that specific product, form and route. They can give you the written information for that product and talk through your concern.
By HealthDataConsortium.org Research Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.

